Floatz logo

Exenatide

Hyperinsulinism

University Hospital, Basel, Switzerlandprotein_peptideDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Hyperinsulinism cohort.

Asset / SponsorPhaseRating
Metformin
Attikon Hospital
Phase 4BB
Letrozole
Attikon Hospital
Phase 4BB
Insulin-Like Growth Factor I
Children's Hospital of Philadelphia
Phase 2B
Vigabatrin
University of Arizona
Phase 2CCC
FDOPA
Washington University School of Medicine
Phase 2CCC

View all 12 →

Same molecule, other indications

Exenatide is also rated in:

type 2 diabetes mellitusDormant
BBB
Indicative ·
78 / 100
View asset →
prediabetes syndromeDormant
BBB
Indicative ·
76 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →